Filing Details
- Accession Number:
- 0001209191-15-049205
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-06-02 19:54:38
- Reporting Period:
- 2015-05-29
- Filing Date:
- 2015-06-02
- Accepted Time:
- 2015-06-02 19:54:38
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1459266 | Zs Pharma Inc. | ZSPH | Pharmaceutical Preparations (2834) | 263305698 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1198321 | Farah Champsi | One Embarcadero Center, Suite 3700 San Francisco CA 94111 | No | No | Yes | No | |
1198325 | Daniel Janney | One Embarcadero Center, Suite 3700 San Francisco CA 94111 | No | No | Yes | No | |
1198330 | P Guy Nohra | One Embarcadero Center, Suite 3700 San Francisco CA 94111 | Yes | No | Yes | No | |
1399763 | Alta Partners Viii, L.p. | One Embarcadero Center, Suite 3700 San Francisco CA 94111 | No | No | Yes | No | |
1399894 | Alta Partners Management Viii, Llc | One Embarcadero Center, Suite 3700 San Francisco CA 94111 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2015-05-29 | 124,865 | $58.63 | 3,105,225 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-05-29 | 14,696 | $59.69 | 3,090,529 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-06-01 | 72,520 | $58.00 | 3,018,009 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-06-02 | 84,342 | $56.77 | 2,933,667 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $58.50 - $59.50, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
- These shares were sold by Alta Partners VIII, L.P. ("APVIII"), the holder of record of the securities. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. Guy Nohra, Daniel Janney and Farah Champsi are managing directors of APMVIII and exercise shared voting and investment power with respect to the shares owned by APVIII. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein. Mr. Nohra is also a director of the issuer.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $59.51 - $59.94, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $57.60 - $58.50, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $56.50 - $57.05, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4.